New concepts in lung cancer screening

Although spiral CT has an undeniably impressive ability to detect occult lung cancers in asymptomatic smokers, it is not clear whether screening this patient group will lead to a reduction in disease-specific mortality. The specter of overdiagnosis in lung cancer screening, which manifested during the chest radiograph trials of the 1970s and 1980s, still hangs over screening regimes today. The detection of premalignant lesions by molecular medicine techniques and fluorescence bronchoscopy may allow the development of novel treatments for preinvasive disease, but it is likely that radiologic means of detection will form the front line of any near future screening program. The proposed screening techniques may be new, but their use must be tested against tried and trusted standards of medical practice.

[1]  J. Herndon,et al.  Stage distribution in patients with a small (< or = 3 cm) primary nonsmall cell lung carcinoma. Implication for lung carcinoma screening. , 2001, Cancer.

[2]  M. Tockman,et al.  Expression of early lung cancer detection marker: hnRNP-A2/B1 and its relation to microsatellite alteration in non-small cell lung cancer. , 2001, Lung cancer.

[3]  O S Miettinen,et al.  CT screening for lung cancer: coping with nihilistic recommendations. , 2001, Radiology.

[4]  W C Black,et al.  CT screening for lung cancer: not ready for routine practice. , 2001, Radiology.

[5]  Y. Miller,et al.  Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study. , 2001, Journal of the National Cancer Institute.

[6]  Rosalie J. Hagge,et al.  Positron emission tomography: brain tumors and lung cancer. , 2001 .

[7]  J. Nikliński,et al.  Molecular genetic abnormalities in premalignant lung lesions: biological and clinical implications , 2001, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[8]  F V Gleeson,et al.  Lung cancer screening. , 2001, The British journal of radiology.

[9]  J. Gohagan,et al.  The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. , 2000, Controlled clinical trials.

[10]  H. Ohmatsu,et al.  Computed tomography screening for lung carcinoma in Japan , 2000, Cancer.

[11]  S. Moss,et al.  Lung cancer screening , 2000, Cancer.

[12]  Gary M. Strauss Randomized population trials and screening for lung cancer , 2000, Cancer.

[13]  O S Miettinen,et al.  Screening for lung cancer , 2000, Cancer.

[14]  C. MacAulay,et al.  Detection and localization of early lung cancer by fluorescence bronchoscopy , 2000, Cancer.

[15]  Ami A. Shah,et al.  Deep venous thrombosis: detection by using indirect CT venography. The Pulmonary Angiography-Indirect CT Venography Cooperative Group. , 2000, Radiology.

[16]  P C Prorok,et al.  Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. , 2000, Journal of the National Cancer Institute.

[17]  P C Goodman,et al.  Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer. , 2000, Chest.

[18]  H Nakata,et al.  Evolution of peripheral lung adenocarcinomas: CT findings correlated with histology and tumor doubling time. , 2000, AJR. American journal of roentgenology.

[19]  D. Fukumura,et al.  Cells shed from tumours show reduced clonogenicity, resistance to apoptosis, and in vivo tumorigenicity , 1999, British journal of cancer.

[20]  O. Miettinen,et al.  Early Lung Cancer Action Project: overall design and findings from baseline screening , 1999, The Lancet.

[21]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[22]  R. Coleman,et al.  The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma , 1998, Cancer.

[23]  J. Shih,et al.  Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients. , 1998, Cancer research.

[24]  Feng Li,et al.  Mass screening for lung cancer with mobile spiral computed tomography scanner , 1998, The Lancet.

[25]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[26]  K. Pantel,et al.  Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases , 1996, The Lancet.

[27]  A. Cochran,et al.  Frequency and distribution of occult micrometastases in lymph nodes of patients with non-small-cell lung carcinoma. , 1993, Journal of the National Cancer Institute.

[28]  C. Wells,et al.  More lung cancer but better survival. Implications of secular trends in "necropsy surprise" rates. , 1989, Chest.

[29]  G. Byrnes,et al.  Screening for lung cancer. , 2004, The Cochrane database of systematic reviews.

[30]  A. Gazdar,et al.  Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  J. Holland Breaking the Cure Barrier , 1983 .